Haemonetics Corp
NYSE:HAE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
71.16
97.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Haemonetics Corp
Haemonetics Corp
Cost of Revenue
Haemonetics Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Haemonetics Corp
NYSE:HAE
|
Cost of Revenue
-$625.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-26%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cost of Revenue
-$527.2m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-11%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cost of Revenue
-$705m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
Haemonetics Corp
Glance View
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.
See Also
What is Haemonetics Corp's Cost of Revenue?
Cost of Revenue
-625.9m
USD
Based on the financial report for Sep 28, 2024, Haemonetics Corp's Cost of Revenue amounts to -625.9m USD.
What is Haemonetics Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Haemonetics Corp have been -8% over the past three years , -4% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
